Pomegra
Heidelberg's Revier Therapeutics closes a €6M seed round to advance the first selective class IIa HDAC inhibitor targeting heart failure and atherosclerosis, spun out of Heidelberg University.
- €6M seed round closed August 25, 2026, led by KHAN Technology Transfer Fund II with HTGF and VORNvc co-investing.
- Revier targets class IIa HDACs, a mechanism no approved cardiovascular drug currently exploits.
- Lead program addresses HFpEF, a heart failure subtype with no approved disease-modifying therapy.
Lead
Revier Therapeutics, a Heidelberg-based biotech spun out of Heidelberg University, emerged from stealth on August 25, 2026, with a €6 million seed round led by KHAN Technology Transfer Fund II. Co-investors include High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. The company is advancing orally available small molecules that selectively inhibit class IIa histone deacetylases (HDACs) - a mechanism that has drawn pharmaceutical interest in oncology for years but has never been translated into a cardiovascular drug.
What Makes Class IIa HDAC Inhibition Different?
Broad HDAC inhibition is already clinically validated, but the drugs that do it - approved cancer agents like vorinostat - carry toxicity profiles that rule out systemic use in cardiovascular patients. Revier's design is more precise. Its small molecules block only the pathogenic enzymatic activity driving cardiometabolic disease, while preserving the healthy functions of both class IIa HDACs and canonical class I HDACs. That selectivity is the company's core claim, and the science behind it comes from Prof. Johannes Backs, MD, director of the Institute of Experimental Cardiology at Heidelberg University and Revier's scientific founder, whose foundational work defined how class IIa HDACs drive cardiac and vascular pathology.
Why Is HFpEF the Lead Indication?
Heart failure with preserved ejection fraction affects roughly half of all heart failure patients - estimated at tens of millions globally - yet no drug has demonstrated disease modification in this population. Existing therapies address symptoms; none act at the epigenetic mechanisms that drive the disease. That gap gives Revier a defensible clinical rationale for its lead program. The company's second program targets atherosclerotic cardiovascular disease (ASCVD), the arterial plaque accumulation underlying most heart attacks and strokes, where competition is considerably stiffer and established lipid-lowering therapies already dominate standard of care.
The Team and Its Institutional Anchors
CEO and co-founder Eva van Rooij, a professor of molecular cardiology at University Medical Center Utrecht, is a serial biotech entrepreneur. Prof. Norbert Frey, MD, Chief Medical Officer, directs the Department of Cardiology, Angiology and Pneumology at Heidelberg University Hospital - giving the company direct proximity to a major cardiac clinical center. Few preclinical seed-stage companies carry both a serial-founding CEO and an active clinical department head as CMO at launch. The combination of university IP provenance, entrepreneurial experience, and institutional clinical access is structurally stronger than external licensing deals typically allow.
The Investor Logic
KHAN Technology Transfer Fund focuses specifically on commercializing European academic IP, making Revier's Heidelberg University origin a natural fit. High-Tech Gründerfonds, Germany's most active early-stage deep-tech investor, adds operational depth across dozens of prior life science spinouts. VORNvc rounds out a syndicate with a clear scientific mandate over early commercial diversification - the right mix for a company still at the preclinical stage. The €6 million total is modest relative to comparable cardiovascular epigenetics programs in the U.S., where seed rounds for mechanism-validation plays regularly exceed $15 million. In Germany's capital environment, it is a credible amount to reach the next meaningful milestone: IND-enabling preclinical data. No valuation was disclosed.
Outlook
Revier's thesis rests on two claims that remain preclinical: that class IIa HDAC selectivity is pharmacologically achievable at therapeutic doses, and that the mechanism produces disease modification rather than symptomatic benefit in humans. The Heidelberg academic record is substantive, but the gap between cardiac biology findings and a cardiovascular drug candidate is wide and has swallowed better-funded programs before. The €6 million will fund preclinical pipeline development and team build-out. If the selectivity profile holds in pharmacological models, Revier will have a rare asset - a first-in-class cardiovascular mechanism with deep institutional roots and a clinical rationale built on decades of peer-reviewed science rather than a platform hypothesis. A Series A will require IND-enabling data, and at that point the company's claims about precision targeting will face a harder test.
